Amarillo Biosciences Enters Into License And Supply Agreement With CytoPharm For Low Dose Oral Interferon Use In Influenza And Hepatitis B In China And Taiwan

AMARILLO, TX and TAIPEI, TAIWAN -- (MARKET WIRE) -- November 27, 2006 -- Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that it has entered into a License and Supply Agreement with CytoPharm, Inc., a Taipei, Taiwan-based biopharmaceutical company whose parent company is Vita Genomics, Inc., the largest biotech company in Taiwan specializing in pharmacogenomics and specialty Clinical Research Organization.